Sustained and Improved Efficacy of Tildrakizumab from Week 28 to Week 52 in Treating Moderate-to-Severe Plaque Psoriasis. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 2, n. S1, p. S22, 2018. DOI: 10.25251/skin.2.supp.22. Disponível em: https://skin.dermsquared.com/skin/article/view/305. Acesso em: 22 may. 2026.